Skip to content

CT and pathology image-based machine learning for preoperative prediction of microvascular invasion in primary hepatocellular carcinoma

CT and pathology image-based machine learning for preoperative prediction of microvascular invasion in primary hepatocellular carcinoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036965
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Gold Standard:Pathology section, HE staining, microscopic multiples view, microvascular carcinoma thrombus (mVI) invasion is defined as a nesting mass of cancer cells within the endothelial cell-lined
Diagnostic&#32

Sponsors

Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 18 and 80, regardless of gender. 2. Patients with primary liver cancer, preoperative upper abdominal stage 3 CT scan. 3. Preoperative liver function Child grade A or B, prothrombin time (PT) less than 4 seconds of normal control. No hepatic encephalopathy or/and significant ascites. Renal function and cardiopulmonary function are basically normal. Hemoglobin >= 90 g/L, white blood cell count >= 3.0 x 10^9/L, neutrophil count >= 1.5 x 10^9/L, and platelet count >= 60 x 10^9/L. 4. Those who can understand the study and have signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who have received chemotherapy, biological therapy, or participated in clinical trials of other drugs or devices prior to enrollment. 2. Preoperative assessment without indication for surgical resection. 3. Who are expected to be unable to tolerate surgical treatment after preoperative assessment of liver function. 4. Persons with obvious contraindications such as hepatic, renal and cardiac insufficiency and those who, in the opinion of the investigator, should not participate in this trial for other reasons.

Design outcomes

Primary

MeasureTime frame
accuracy;reliabiliy;

Secondary

MeasureTime frame
predictive value;

Countries

China

Contacts

Public ContactGuo Lei

Eastern Hepatobiliary Surgery Hospital, Second Military Medical University

goto.st@outlook.com+86 15921811650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026